Legis Daily

Shandra Eisenga Human Cell and Tissue Product Safety Act

USA118th CongressHR-7188| House 
| Updated: 12/17/2024
John R. Moolenaar

John R. Moolenaar

Republican Representative

Michigan

Cosponsors (1)
Debbie Dingell (Democratic)

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Shandra Eisenga Human Cell and Tissue Product Safety Act This bill requires federal agencies to update guidance, regulations, and educational materials about transplants involving human cell and tissue products, particularly with respect to safety and eligibility standards. Specifically, the Department of Health and Human Services must support the development of educational materials for health care providers about issues relating to organ, tissue, and eye donations; screening tests; and other aspects of donations. The Food and Drug Administration (FDA) must review current guidance on donor eligibility and, if appropriate, update it with information on how to reduce the spread of tuberculosis or sepsis in association with donations. The FDA must also publish information about its Tissue Reference Group and data about FDA inspections and registrations of human cell and tissue establishments. The bill also establishes specific civil penalties for violations of regulations governing procedures for human cell and tissue products. The FDA must consider and recommend ways to update these regulations after a public comment period.

Bill Text Versions

View Text
4 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 1, 2024
Introduced in House
Feb 1, 2024
Referred to the House Committee on Energy and Commerce.
Feb 2, 2024
Referred to the Subcommittee on Health.
Feb 5, 2024

Latest Companion Bill Action

S 118-3733
Introduced in Senate
May 16, 2024
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 27 - 0.
May 16, 2024
Subcommittee Consideration and Mark-up Session Held
Sep 18, 2024
Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 0.
Sep 18, 2024
Committee Consideration and Mark-up Session Held
Nov 22, 2024
Placed on the Union Calendar, Calendar No. 632.
Nov 22, 2024
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-766.
Dec 16, 2024
Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
Dec 16, 2024
Considered under suspension of the rules. (consideration: CR H7167-7170)
Dec 16, 2024
DEBATE - The House proceeded with forty minutes of debate on H.R. 7188.
Dec 16, 2024
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
Dec 16, 2024
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
Dec 16, 2024
Motion to reconsider laid on the table Agreed to without objection.
Dec 17, 2024
Received in the Senate.
  • February 1, 2024
    Introduced in House


  • February 1, 2024
    Referred to the House Committee on Energy and Commerce.


  • February 2, 2024
    Referred to the Subcommittee on Health.


  • February 5, 2024

    Latest Companion Bill Action

    S 118-3733
    Introduced in Senate


  • May 16, 2024
    Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 27 - 0.


  • May 16, 2024
    Subcommittee Consideration and Mark-up Session Held


  • September 18, 2024
    Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 0.


  • September 18, 2024
    Committee Consideration and Mark-up Session Held


  • November 22, 2024
    Placed on the Union Calendar, Calendar No. 632.


  • November 22, 2024
    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-766.


  • December 16, 2024
    Mr. Bucshon moved to suspend the rules and pass the bill, as amended.


  • December 16, 2024
    Considered under suspension of the rules. (consideration: CR H7167-7170)


  • December 16, 2024
    DEBATE - The House proceeded with forty minutes of debate on H.R. 7188.


  • December 16, 2024
    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)


  • December 16, 2024
    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)


  • December 16, 2024
    Motion to reconsider laid on the table Agreed to without objection.


  • December 17, 2024
    Received in the Senate.

Health

Related Bills

  • S 118-3733: Shandra Eisenga Human Cell and Tissue Product Safety Act
Administrative law and regulatory proceduresCivil actions and liabilityCongressional oversightDepartment of Health and Human ServicesHealth programs administration and fundingHealth promotion and preventive careOrgan and tissue donation and transplantation

Shandra Eisenga Human Cell and Tissue Product Safety Act

USA118th CongressHR-7188| House 
| Updated: 12/17/2024
Shandra Eisenga Human Cell and Tissue Product Safety Act This bill requires federal agencies to update guidance, regulations, and educational materials about transplants involving human cell and tissue products, particularly with respect to safety and eligibility standards. Specifically, the Department of Health and Human Services must support the development of educational materials for health care providers about issues relating to organ, tissue, and eye donations; screening tests; and other aspects of donations. The Food and Drug Administration (FDA) must review current guidance on donor eligibility and, if appropriate, update it with information on how to reduce the spread of tuberculosis or sepsis in association with donations. The FDA must also publish information about its Tissue Reference Group and data about FDA inspections and registrations of human cell and tissue establishments. The bill also establishes specific civil penalties for violations of regulations governing procedures for human cell and tissue products. The FDA must consider and recommend ways to update these regulations after a public comment period.

Bill Text Versions

View Text
4 versions available

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Feb 1, 2024
Introduced in House
Feb 1, 2024
Referred to the House Committee on Energy and Commerce.
Feb 2, 2024
Referred to the Subcommittee on Health.
Feb 5, 2024

Latest Companion Bill Action

S 118-3733
Introduced in Senate
May 16, 2024
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 27 - 0.
May 16, 2024
Subcommittee Consideration and Mark-up Session Held
Sep 18, 2024
Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 0.
Sep 18, 2024
Committee Consideration and Mark-up Session Held
Nov 22, 2024
Placed on the Union Calendar, Calendar No. 632.
Nov 22, 2024
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-766.
Dec 16, 2024
Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
Dec 16, 2024
Considered under suspension of the rules. (consideration: CR H7167-7170)
Dec 16, 2024
DEBATE - The House proceeded with forty minutes of debate on H.R. 7188.
Dec 16, 2024
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
Dec 16, 2024
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
Dec 16, 2024
Motion to reconsider laid on the table Agreed to without objection.
Dec 17, 2024
Received in the Senate.
  • February 1, 2024
    Introduced in House


  • February 1, 2024
    Referred to the House Committee on Energy and Commerce.


  • February 2, 2024
    Referred to the Subcommittee on Health.


  • February 5, 2024

    Latest Companion Bill Action

    S 118-3733
    Introduced in Senate


  • May 16, 2024
    Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 27 - 0.


  • May 16, 2024
    Subcommittee Consideration and Mark-up Session Held


  • September 18, 2024
    Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 0.


  • September 18, 2024
    Committee Consideration and Mark-up Session Held


  • November 22, 2024
    Placed on the Union Calendar, Calendar No. 632.


  • November 22, 2024
    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-766.


  • December 16, 2024
    Mr. Bucshon moved to suspend the rules and pass the bill, as amended.


  • December 16, 2024
    Considered under suspension of the rules. (consideration: CR H7167-7170)


  • December 16, 2024
    DEBATE - The House proceeded with forty minutes of debate on H.R. 7188.


  • December 16, 2024
    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)


  • December 16, 2024
    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)


  • December 16, 2024
    Motion to reconsider laid on the table Agreed to without objection.


  • December 17, 2024
    Received in the Senate.
John R. Moolenaar

John R. Moolenaar

Republican Representative

Michigan

Cosponsors (1)
Debbie Dingell (Democratic)

Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • S 118-3733: Shandra Eisenga Human Cell and Tissue Product Safety Act
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Administrative law and regulatory proceduresCivil actions and liabilityCongressional oversightDepartment of Health and Human ServicesHealth programs administration and fundingHealth promotion and preventive careOrgan and tissue donation and transplantation